Pliant Therapeutics reported net income of -$22.43M for the quarter ended Jun 2026. This income statement covers 29 quarters of results from Jun 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 35.98M | 36.08M | 36.16M | 36.18M | 48.75M | 48.94M | 58.98M | 59.22M | 59.89M | 59.92M | 60.32M | 60.43M | 60.85M | 60.86M | 61.39M | 61.39M | 61.45M | 61.45M | 61.91M | 61.92M | |||||||||
| Revenue & cost | |||||||||||||||||||||||||||||
| Revenue | 1.61M | 2.00M | 1.25M | 4.99M | 1.48M | 1.97M | 1.33M | 0.25M | |||||||||||||||||||||
| Operating items | |||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 21.05M | 18.75M | 20.88M | 26.34M | 24.61M | 25.11M | 29.27M | 33.00M | 32.34M | 33.18M | 37.15M | 45.62M | 47.75M | 38.79M | 43.44M | 32.20M | 17.94M | 15.59M | 13.58M | 16.73M | |||||||||
| Selling, General & AdministrativeSG&A | 7.67M | 7.85M | 8.58M | 8.30M | 8.82M | 14.25M | 14.15M | 14.57M | 15.35M | 13.85M | 15.25M | 15.02M | 14.26M | 14.53M | 15.50M | 13.39M | 10.33M | 7.99M | 8.19M | 7.13M | |||||||||
| Operating ExpensesOpex | 28.72M | 26.60M | 29.46M | 34.63M | 33.43M | 39.37M | 43.43M | 47.58M | 47.69M | 47.04M | 52.39M | 60.64M | 62.01M | 53.32M | 58.94M | 45.59M | 28.27M | 23.58M | 21.77M | 23.86M | |||||||||
| Operating IncomeOp. Inc | -27.11M | -24.60M | -28.21M | -29.64M | -31.95M | -37.40M | -42.09M | -47.33M | -47.69M | -47.04M | -52.39M | -60.64M | -62.01M | -53.32M | -58.94M | -45.59M | -28.27M | -23.58M | -21.77M | -23.86M | |||||||||
| EBIT | -27.11M | -24.60M | -28.21M | -29.64M | -31.95M | -37.40M | -42.09M | -47.33M | -47.69M | -47.04M | -52.39M | -60.64M | -62.01M | -53.32M | -58.94M | -45.59M | -28.27M | -23.58M | -21.77M | -23.86M | |||||||||
| Non-operating items | |||||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.17M | 0.30M | 0.32M | 0.31M | 0.32M | 0.32M | 0.32M | 0.45M | 0.87M | 0.88M | 0.83M | 0.80M | 0.81M | 0.81M | 0.14M | ||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.07M | 0.07M | -0.75M | -0.31M | 1.63M | 6.92M | 0.63M | -0.91M | 6.51M | 6.25M | -0.83M | -0.13M | 5.13M | 4.42M | -0.16M | 3.10M | 2.78M | 1.96M | -0.33M | 1.49M | |||||||||
| Other Non Operating IncomeOther Non Op Inc. | |||||||||||||||||||||||||||||
| Net income details | |||||||||||||||||||||||||||||
| EBT | -27.05M | -24.53M | -28.96M | -30.12M | -30.61M | -30.79M | -41.78M | -48.56M | -41.49M | -41.11M | -53.67M | -61.63M | -57.76M | -49.73M | -59.90M | -43.30M | -26.30M | -21.75M | -22.10M | -22.37M | |||||||||
| Profit After TaxPAT | -27.05M | -24.69M | -28.10M | -29.55M | -31.81M | -34.56M | -37.55M | -41.19M | -41.49M | -41.11M | -46.95M | -55.85M | -57.76M | -49.76M | -56.17M | -43.46M | -26.30M | -23.63M | -20.04M | -22.43M | |||||||||
| Income from Continuing OperationsIncome (Continuing) | -27.05M | -24.53M | -28.96M | -30.12M | -30.61M | -30.79M | -41.78M | -48.56M | -41.49M | -41.11M | -53.67M | -61.63M | -57.76M | -49.73M | -59.90M | -43.30M | -26.30M | -21.75M | -22.10M | -22.37M | |||||||||
| Consolidated Net IncomeConsol Net Inc. | -27.05M | -24.53M | -28.96M | -30.12M | -30.61M | -30.79M | -41.78M | -48.56M | -41.49M | -41.11M | -53.67M | -61.63M | -57.76M | -49.73M | -59.90M | -43.30M | -26.30M | -21.75M | -22.10M | -22.37M | |||||||||
| Income towards Parent CompanyParent Net Inc | -27.05M | -24.53M | -28.96M | -30.12M | -30.61M | -30.79M | -41.78M | -48.56M | -41.49M | -41.11M | -53.67M | -61.63M | -57.76M | -49.73M | -59.90M | -43.30M | -26.30M | -21.75M | -22.10M | -22.37M | |||||||||
| Preferred Dividend PaymentsPref Dividends | |||||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -27.05M | -24.53M | -28.10M | -29.55M | -30.61M | -35.06M | -37.55M | -41.19M | -41.49M | -41.11M | -53.67M | -61.63M | -57.76M | -49.73M | -59.90M | -43.30M | -26.30M | -21.75M | -22.10M | -22.37M | |||||||||
| Additional items | |||||||||||||||||||||||||||||
| EPS (Basic) | -0.75 | -0.68 | -0.78 | -0.82 | -0.65 | -0.83 | -0.67 | -0.70 | -0.70 | -0.70 | -0.89 | -1.02 | -0.95 | -0.82 | -0.98 | -0.71 | -0.43 | -0.35 | -0.36 | -0.36 | |||||||||
| EPS (Diluted) | -0.75 | -0.68 | -0.78 | -0.82 | -0.65 | -0.83 | -0.67 | -0.70 | -0.70 | -0.70 | -0.89 | -1.02 | -0.95 | -0.82 | -0.98 | -0.71 | -0.43 | -0.35 | -0.36 | -0.36 | |||||||||
| Shares Outstanding | 35.91M | 35.85M | 36.12M | 36.17M | 46.80M | 42.02M | 56.06M | 59.17M | 59.69M | 58.72M | 60.18M | 60.38M | 60.73M | 60.54M | 61.22M | 61.39M | 61.41M | 61.37M | 61.80M | 61.92M | |||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 35.91M | 35.85M | 36.12M | 36.17M | 46.80M | 42.02M | 56.06M | 59.17M | 59.69M | 58.72M | 60.18M | 60.38M | 60.73M | 60.54M | 61.22M | 61.39M | 61.41M | 61.37M | 61.80M | 61.92M | |||||||||
| EBITDA | -27.11M | -24.60M | -28.21M | -29.64M | -31.95M | -37.40M | -42.09M | -47.33M | -47.69M | -47.04M | -52.39M | -60.64M | -62.01M | -53.32M | -58.94M | -45.59M | -28.27M | -23.58M | -21.77M | -23.86M | |||||||||
| Interest ExpensesInt Expense | 0.17M | 0.30M | 0.32M | 0.31M | 0.32M | 0.32M | 0.32M | 0.45M | 0.87M | 0.88M | 0.83M | 0.80M | 0.81M | 0.81M | 0.14M |